Ryan Scott

Articles

Nivolumab Plus Talazoparib Does Not Induce Responses in Heavily Pretreated Melanoma

April 10th 2024

Nivolumab plus talazoparib did not produce RECIST-based tumor responses in heavily pretreated patients with unresectable or metastatic melanoma.

FDA Accepts NDA for SH-201 in Leukemia and Other Cancers

April 8th 2024

The FDA has accepted for review the new drug application for SH-201 for the treatment of patients with certain forms of leukemia and other cancers.

FDA Grants Breakthrough Therapy Designation to First-Line Sunvozertinib for EGFR Exon 20+ NSCLC

April 8th 2024

The FDA has granted breakthrough therapy designation to sunvozertinib for patients with locally advanced or metastatic NSCLC with an EGFR exon 20 insertion mutation.

Personalized Cancer Vaccine Leads to Delays in Pancreatic Cancer Recurrence

April 7th 2024

Adjuvant treatment with the personalized neoantigen vaccine, autogene cevumeran, delayed pancreatic cancer recurrence in pancreatic ductal adenocarcinoma.

Sotomayor Elucidates Updates Including ADC and Bispecific Antibody Combinations in Hematology

April 6th 2024

Eduardo M. Sotomayor, MD, discusses updates in the treatment of hematologic malignancies, highlighting research on antibody-drug conjugate and bispecific antibody combinations.

Phase 2 Data Support Use of RNX-051 in Cancerous and Precancerous CRC

April 5th 2024

RNX-051 displays impact on bacterial biomass in patients with right-sided colorectal cancer and right-sided colon polyps/adenomas.

Targeted Therapies Are Finding Their Footing in Hematologic Malignancies

April 4th 2024

Eduardo M. Sotomayor, MD, expands on the evolving treatment paradigm for hematologic malignancies, highlighting treatment with CAR T-cell therapy.

Neoadjuvant and Adjuvant Trials Could Continue to Individualize Treatment in MIBC

April 4th 2024

Bernard H. Bochner, MD, FACS, discusses updates in the treatment of muscle-invasive bladder cancer and ongoing trials in the space.

CAN-2409 Plus Valacyclovir Generates Positive Phase 2 Survival Results in PDAC

April 4th 2024

Positive phase 2 findings for CAN-2409 plus valacyclovir in pancreatic ductal adenocarcinoma have been reported.

Breaking Down the Utility of Vepdegestrant in First-Line ER+/HER2– Breast Cancer

April 3rd 2024

Carlos L. Arteaga, MD, discusses the utility of vepdegestrant alone or in combination in patients with ER-positive, HER2-negative advanced breast cancer.

Insights, Innovations, and Challenges Ahead in the Treatment of Urothelial Carcinoma

April 3rd 2024

Daniel P. Petrylak, MD, discusses the importance of molecularly-driven clinical trials and ongoing research with novel therapeutics in urothelial carcinoma.

Ongoing Research Pushes for Neoadjuvant Alternatives to Chemotherapy in MIBC

April 1st 2024

Bernard H. Bochner, MD, FACS, highlights advancements in early-stage muscle-invasive bladder cancer and the necessity for multimodality approaches.

Ongoing Trials Aim to Build on Systemic Therapy Combinations in Advanced RCC

April 1st 2024

Wenxin (Vincent) Xu, MD, shares recent updates in the treatment of renal cell carcinoma, including insights into ongoing research and trials within the space.

Recent FDA Approvals in Advanced Urothelial Carcinoma Propel Treatment Forward

March 31st 2024

Daniel P. Petrylak, MD, discusses advancements in the treatment of patients with bladder cancer.

Establishing Biomarkers Is Key to Driving Personalized Systemic Treatment Choices in Advanced RCC

March 30th 2024

Wenxin (Vincent) Xu, MD, discusses the evolving landscape of systemic therapy in RCC, sharing how he makes treatment decisions amid the changing treatment space.

TTFields Meets Time to Intracranial Progression End Point in NSCLC Brain Metastases

March 27th 2024

TTFields plus supportive care improved time to intracranial progression in patients with brain metastases from non–small cell lung cancer.

Clearer Definitions of Added Benefit, Unmet Needs Could Improve EU Oncologic Drug Approval Process

March 27th 2024

Investigators emphasize the importance of firming a widely understood definition of unmet needs in cancer care due to their impact on drug approvals.

Navigating First-Line Treatment Options in Advanced, Unresectable HCC

March 26th 2024

Pierre Gholam, MD, discusses primary considerations for the first-line treatment of patients with advanced, unresectable HCC.

First-Line Anlotinib Plus Etoposide and Carboplatin Improves PFS in ES-SCLC

March 25th 2024

Anlotinib plus etoposide, carboplatin, and placebo improved PFS vs etoposide plus carboplatin and 2 placebos in first-line ES-SCLC.

Enzalutamide Receives Positive EU CHMP Opinion for High-Risk Biochemically Recurrent nmHSPC

March 22nd 2024

The EMA’s CHMP has recommended the approval of enzalutamide with or without androgen deprivation therapy in biochemically recurrent nmHSPC.